Table IIB.
Hematopoietic stem cell transplantation procedure and outcome
| Patient | Age at HSCT (years) | Pre-treatment | Conditioning regimen | Bu AUC (mg* h/L) | GVHD prophylaxis | Donor type | Donor cell source | Cell dose (×106 CD34+ cells/kg) | Day of neutrophil engraftment | Complications | GVHD | Chimerism at last measurement (years post-HSCT) | Status (years post-HSCT) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 | 6.2 | Alemtuzumab/Flu/Melphalan | n/a | CSA/MMF | mMURD (8/10) | PB | 10 | n/a | - | T cell: 89% B cell: 11% Myeloid: 0% (2.0) |
A&W (4.4) | ||
| 9 | 3.4 | Bu/Flu/eATG | 85.6 | CSA/MTX/prednisone | MURD | BM | 3.65 | 21 | CMV reactivation | - | T cell: 100% B cell: 100% Myeloid: 100% (3.1) |
A&W (3.5) | |
| 10 | 2.3 | Alemtuzumab/Flu/Melphalan | n/a | CSA/MMF | mMURD (9/10) | PB | 23.72 | 15 | EBV viremia | - | T cell: 82% B cell: 0% Myeloid: 0% (1.8) |
A&W (2.8) | |
| 11 | 2.1 | Bu/Flu/eATG | 80.6 | CSA/MTX/prednisone | mMURD (9/10) | BM | 2.26 | 34 | HSV viremia, ezcema herpeticum, Enterobacter bacteremia | - | T cell: 97% B cell: 46% Myeloid: 7% (2.5) |
A&W (2.8) |
A&W: alive and well, ATG: anti-thymocyte globulin (equine or rabbit), AUC: area under the curve, BM: bone marrow, Bu: busulfan, CMV: cytomegalovirus, CNS: central nervous system, CSA: cyclosporine A, Cy: cyclophosphamide, EBV: Epstein-Barr virus, Flu: fludarabine, GVHD: graft versus host disease, HSCT: hematopoietic stem cell transplantation, HSV: herpes simplex virus, MMF: mycophenolate mofetil, mMURD: mismatched unrelated donor, MSD: matched sibling donor, MTX: methotrexate, MURD: matched unrelated donor, n/a: not available, PB: peripheral blood, RIC: reduced intensity conditioning,